Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03686384 · ClinicalTrials.gov registry record · Phase 3
SVT-15652 Otic Solution for the Treatment of Otomycosis
A Phase 3 study, sponsored by Salvat.
- Completed
- Registry status
- Phase 3
- Development phase
- 217
- Enrollment target
NCT03686384: Completed Phase 3 study, sponsored by Salvat.
NCT03686384 is a Phase 3 study that has completed, run by Salvat. The registered enrollment target is 217 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03686384, a Phase 3 study, has completed, sponsored by Salvat.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 217 participants
- Enrollment target
Study Summary
Multicenter, randomized, 2-arm parallel-group, double blind, placebo-controlled study in patients suffering from Otomycosis. This study will compare the efficacy and safety of SVT-15652 otic solution to that of Placebo, when administering one vial twice daily during 14 days.
Primary Outcome
Number and percentage of subjects with therapeutic cure
Interventions
- DRUG Placebo
- DRUG SVT-15652
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2020-02-27 |
| Est. Completion | 2021-10-25 |
| Phase | Phase 3 |
What the finished NCT03686384 record still lists
NCT03686384 is an interventional study that assigns participants to a tested intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03686384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03686384 about?
NCT03686384 is a clinical study titled "SVT-15652 Otic Solution for the Treatment of Otomycosis". Multicenter, randomized, 2-arm parallel-group, double blind, placebo-controlled study in patients suffering from Otomycosis. This study will compare the efficacy and safety of SVT-15652 otic solution to that of Placebo, when administering one vial twice daily during 14 days.
What is the current status of trial NCT03686384?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 217 participants. The study started on 2020-02-27. Estimated completion is 2021-10-25.
What interventions are being tested in trial NCT03686384?
The interventions under investigation include: Placebo (DRUG), SVT-15652 (DRUG).
Who is sponsoring clinical trial NCT03686384?
This trial is sponsored by Salvat, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03686384's enrollment target sits among peer trials
217 1332nd of 2000 higher than 669 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI